VA
VANI
—
Nasdaq
Medical Equipment, Supplies & Distribution
Vivani Medical, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
108,1M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-35,5 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
5
Day range
—
Prev close
$1,41
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Vivani Medical, Inc. is classified under Healthcare / Biotechnology and appears not currently profitable on the latest normalized snapshot.
Business. Vivani Medical, Inc. (VANI) is a biotechnology company operating within the healthcare sector. The firm is headquartered in the United States and its common stock is listed on the Nasdaq stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · rules-based
Sell-side consensus
BUY4 analysts
4 buy0 hold0 sell
Avg 12m price target4,62
Analyst recommendations
4 analysts · consensus BuyBuy4
Hold0
Sell0
12-month price target
4,62
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
4 analysts · indicative
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability→
-35,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to VANI. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Briefing · model-assisted
Vivani Medical, Inc. (VANI) has recorded its first notable holder change, with an investor adding a position of 1,200 shares as of March 31, 2026. This acquisition, valued at approximately $0.001 million, represents a weight of roughly 0.0000006% of the company’s equity. The change was detected on June 20, 2026, marking the initial significant movement in ownership structure for the ticker. This development is particularly significant as it constitutes the first analysis basis for VANI, with no prior data available for delta computation. Consequently, this single holder addition serves as the primary material change for the company, establishing a baseline for future monitoring of investor activity and ownership concentration. The significance of this entry is contextualized by Vivani Medical’s current corporate profile, which includes zero listed officers and zero analyst coverage. With no index memberships and a total of 11 top holders, the addition of this specific investor highlights the limited but active interest in the company’s equity among a small group of stakeholders. As this is the first recorded analysis for the ticker, the addition of this holder provides the initial reference point for assessing changes in VANI’s shareholder base. The lack of prior basis for delta computation means that this event stands alone as the defining material change, underscoring the early stage of tracked investor engagement for the firm.
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Vivani Medical, Inc. (VANI) is a biotechnology company operating within the healthcare sector. The firm is headquartered in the United States and its common stock is listed on the Nasdaq stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
AI synthesis
GENERATEDVivani Medical, Inc. (VANI) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: total assets 42,353,000 USD, total equity 19,085,000, short-term debt 0, long-term debt 0. Net cash position is approximately 19,749,000 USD. Self-calculated market cap is 109,713,150 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 0, gross profit 0, operating income -6,817,000, net income -6,780,000. Return on equity ~-35.5%. Return on assets ~-16.0%. Operating-cash-flow to net-income ratio is 0.91. Risk profile from automated assessment: liquidity risk low, dilution risk medium. Flags: Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on VANI — filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001753926-26-001144). Additional context: 8-K: filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material.
Vivani Medical, Inc. (VANI) has recorded its first notable holder change, with an investor adding a position of 1,200 shares as of March 31, 2026. This acquisition, valued at approximately $0.001 million, represents a weight of roughly 0.0000006% of the company’s equity. The change was detected on June 20, 2026, marking the initial significant movement in ownership structure for the ticker. This development is particularly significant as it constitutes the first analysis basis for VANI, with no prior data available for delta computation. Consequently, this single holder addition serves as the primary material change for the company, establishing a baseline for future monitoring of investor activity and ownership concentration. The significance of this entry is contextualized by Vivani Medical’s current corporate profile, which includes zero listed officers and zero analyst coverage. With no index memberships and a total of 11 top holders, the addition of this specific investor highlights the limited but active interest in the company’s equity among a small group of stakeholders. As this is the first recorded analysis for the ticker, the addition of this holder provides the initial reference point for assessing changes in VANI’s shareholder base. The lack of prior basis for delta computation means that this event stands alone as the defining material change, underscoring the early stage of tracked investor engagement for the firm.
Key takeaways
- Return on equity is about -35.5%.
- Debt to equity is about 0.0x.
- [TRIGGER] 8-K: 8-K (sec_8k_material) on VANI — filing_type=8-K; max_severity=high; ignored_items=['8.01', '9.01']; material_items=['1.01']; all_items_found=['1.01', '8.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001753926-26-001144)
- vani-20260331.htm false Q1 2026 --12-31 0001266806 0.33 0.33 CA 76,428 false false false false 0001266806 2026-01-01 2026-03-31 0001266806 2025-01-01 2025-03-31 0001266806 2026-03-31 0001266806 2025-03-31 0001266806 2025-12-31 0001266806 us-gaap:CommonStockMember 2026-03-31 0001266806 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001266806 us-gaap:RetainedEarningsMember 2026-03-31 0001266806 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001266806 us-gaap:CommonStockMember 2025-12-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001266806 us-gaap:RetainedEarningsMember 2025-12-31 0001266806 us-gaap:CommonStockMember 2024-12-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001266806 us-gaap:RetainedEarningsMember 2024-12-31 0001266806 2024-12-31 0001266806 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001266806 us-gaap:CommonStockMember 2025-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001266806 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001266806 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001266806 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001266806 us-gaap:RetainedEarningsMember 2025-03-31 0001266806 2026-07-15 0001266806 country:AU 2025-03-31 0001266806 country:AU 2026-03-31 0001266806 us-gaap:MoneyMarketFundsMember 2026-03-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001266806 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001266806 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001266806 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001266806 us-gaap:MoneyMarketFundsMember 2025-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001266806 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001266806 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001266806 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001266806 us-gaap:LoansPayableMember 2024-09-30 0001266806 us-gaap:LoansPayableMember 2025-09-30 0001266806 us-gaap:LoansPayableMember 2025-09-01 2025-09-30 0001266806 us-gaap:EquipmentMember 2026-03-31 0001266806 us-gaap:FurnitureAndFixturesMember 2026-03-31 0001266806 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2026-03-31 0001266806 us-gaap:ConstructionInProgressMember 2026-03-31 0001266806 us-gaap:EquipmentMember 2025-12-31 0001266806 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001266806 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-12-31 0001266806 us-gaap:ConstructionInProgressMember 2025-12-31 0001266806 us-gaap:LoansPayableMember 2026-03-31 0001266806 us-gaap:LoansPayableMember 2024-09-01 2024-09-30 0001266806 us-gaap:CommonStockMember vani:SecuritiesPurchaseAgreementMember 2024-03-01 0001266806 us-gaap:CommonStockMember vani:SecuritiesPurchaseAgreementMember us-gaap:WarrantMember 2024-03-01 0001266806 vani:SecuritiesPurchaseAgreementMember us-gaap:WarrantMember 2024-03-01 0001266806 vani:EquityIncentivePlansMember 2026-03-31 0001266806 vani:EquityIncentivePlansMember us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001266806 vani:SecuritiesPurchaseAgreementMember vani:JefferiesLlcMember 2024-04-22 0001266806 vani:SalesAgreementMember vani:JefferiesLlcMember 2024-04-22 0001266806 vani:SalesAgreementMember vani:JefferiesLlcMember 2024-04-22 2024-04-22 0001266806 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001266806 us-gaap:EmployeeStockOptionMember 2026-03-31 0001266806 vani:SalesAgreementMember 2025-01-01 2025-03-31 0001266806 us-gaap:CommonStockMember vani:SalesAgreementMember 2025-01-01 2025-03-31 0001266806 us-gaap:EmployeeStockOptionMember 2025-12-31 0001266806 vani:EntityAffiliatedWithDirectorMember us-gaap:PrivatePlacementMember 2025-03-26 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001266806 us-gaap:WarrantMember 2025-12-31 0001266806 vani:EntityAffiliatedWithDirectorMember us-gaap:PrivatePlacementMember 2025-03-26 2025-03-26 0001266806 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-03-31 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2026-01-01 2026-03-31 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001266806 us-gaap:WarrantMember 2026-03-31 0001266806 vani:IndependentDirectorOneMember us-gaap:PrivatePlacementMember 2025-05-12 0001266806 vani:EntityAffiliatedWithDirectorMember us-gaap:PrivatePlacementMember 2025-05-12 0001266806 vani:IndependentDirectorOneMember us-gaap:PrivatePlacementMember 2025-05-12 2025-05-12 0001266806 vani:EntityAffiliatedWithDirectorAndInvestorMember us-gaap:PrivatePlacementMember 2025-08-11 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001266806 vani:IndependentDirectorOneMember us-gaap:PrivatePlacementMember 2025-08-11 0001266806 vani:IndependentDirectorOneMember us-gaap:PrivatePlacementMember 2025-08-11 2025-08-11 0001266806 vani:EntityAffiliatedWithDirectorAndInvestorMember us-gaap:PrivatePlacementMember 2026-01-01 2026-03-31 0001266806 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2026-01-01 2026-03-31 0001266806 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2026-01-01 2026-03-31 0001266806 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2025-01-01 2025-03-31 0001266806 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001266806 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2025-01-01 2025-03-31 0001266806 us-gaap:PrivatePlacementMember 2026-01-01 2026-03-31 0001266806 vani:NanoPrecisionMedicalIncWarrantMember 2026-01-01 2026-03-31 0001266806 vani:RightOfferingMember 2026-01-01 2026-03-31 0001266806 vani:NanoPrecisionMedicalIncWarrantMember 2026-03-31 0001266806 vani:NanoPrecisionMedicalIncWarrantMember 2019-01-01 2019-12-31 0001266806 us-gaap:WarrantMember vani:SecuritiesPurchaseAgreementMember 2026-03-31 0001266806 vani:StockOptionsMember 2026-01-01 2026-03-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001266806 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001266806 vani:StockOptionsMember 2025-01-01 2025-03-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001266806 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001266806 2022-01-01 2022-12-31 0001266806 2024-01-26 2024-01-26 0001266806 vani:AlamedaCAMember 2022-11-21 0001266806 vani:AlamedaCAMember 2022-11-19 2022-11-21 0001266806 vani:AlamedaCAMember 2022-11-21 2022-11-21 0001266806 vani:LessorMember 2023-01-31 2023-02-01 0001266806 2023-02-01 2023-02-01 0001266806 vani:SubleaseStorageSpaceMember 2023-02-01 2023-02-01 0001266806 vani:LessorMember 2026-03-31 0001266806 2021-04-01 0001266806 2021-05-18 2021-05-19 0001266806 2022-12-08 2022-12-08 0001266806 vani:BiopharmDivisionMember 2026-01-01 2026-03-31 0001266806 vani:NeuromodulationDivisionMember 2026-01-01 2026-03-31 0001266806 vani:BiopharmDivisionMember 2026-03-31 0001266806 vani:NeuromodulationDivisionMember 2026-03-31 0001266806 vani:BiopharmDivisionMember 2025-01-01 2025-03-31 0001266806 vani:NeuromodulationDivisionMember 2025-01-01 2025-03-31 0001266806 2026-05-12 0001266806 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001266806 vani:NanoPrecisionMedicalIncWarrantMember 2020-01-01 2020-12-31 0001266806 vani:NanoPrecisionMedicalIncWarrantMember 2021-01-01 2021-12-31 0001266806 us-gaap:WarrantMember vani:SecuritiesPurchaseAgreementMember 2024-03-01 2024-03-01 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001266806 vani:EntityAffiliatedWithDirectorMember us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2026-01-25 0001266806 vani:EntityAffiliatedWithDirectorMember us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2026-01-25 2026-01-25 0001266806 vani:ThinkEquityLlcMember vani:PlacementAgencyAgreementMember 2026-01-25 0001266806 vani:ThinkEquityLlcMember vani:PlacementAgencyAgreementMember 2026-01-25 2026-01-25 0001266806 vani:StockOptionsWithServiceVestingMember 2026-01-01 2026-03-31 0001266806 vani:StockOptionsWithServiceVestingMember 2025-01-01 2025-03-31 0001266806 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-12-31 0001266806 srt:MaximumMember 2026-03-31 0001266806 2024-07-03 2024-07-03 0001266806 vani:SubleaseForManufacturingFacilityMember 2025-10-01 2025-10-01 0001266806 vani:LessorMember 2026-01-01 2026-03-31 0001266806 vani:EntityAffiliatedWithDirectorAndInvestorMember us-gaap:PrivatePlacementMember 2026-03-31 0001266806 vani:ThinkEquityLlcMember vani:PlacementAgencyAgreementMember 2026-01-01 2026-03-31 xbrli:shares xbrli:pure iso4217:EUR utr:sqft iso4217:USD iso4217:USD xbrli:shares vani:NUMBER vani:ITEM vani:SEGMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
- These forward-looking statements include, but are not limited to, statements about: our anticipated operating and financial performance, business plans, and prospects; expectations for our products, including anticipated regulatory submissions, study completion, approvals, clinical trial results and other developing data that become available, potential market size, and potential reimbursement pathways; the timing and likelihood of, and our ability to obtain and maintain, regulatory clearance of our Investigational New Drug (“IND”) applications for and regulatory approval of our product candidates; our ability to successfully scale manufacturing operations in a manner that enables us to complete our clinical trials and if our product candidates are approved, to meet commercial demand; our ability to create and maintain a pipeline of product candidates; our ability to advance any product candidate into, and successfully complete clinical trials; our ability to initiate and successfully maintain operations of our subsidiary in Australia, including with respect to studies of our products and product candidates; the initiation, timing, design, progress and results of our clinical trials, and our research and development program; the anticipated receipt of proceeds from our tranched financings, including our ability to meet closing conditions at each closing; the success of the business, including future capital expenditures, expenses, synergies, economic performance, indebtedness, financial condition, losses, future prospects, and business strategies for the management, expansion and growth of the company’s operations, and other conditions to the successful synergies of the business combination; the effect of unfavorable macroeconomic factors resulting from global economic conditions or geopolitical developments, including fluctuating interest rates and inflation and capital market disruptions, changes in governmental agencies, government shutdowns, international tariffs, trade protection measures, public health crises, economic sanctions and potential economic slowdowns or recessions, or similar events that could impact our business; the impact of laws and regulations in the United States and foreign countries on various aspects of our operations, including our regulatory and clinical strategy; and other risks and uncertainties, including those listed under the caption “Risk Factors.” Any forward-looking statements in this Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties, assumptions and other factors described under the “Risk Factors” section and elsewhere in this Form 10-Q, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Operating income -$6.8M.
Revenue—
Operating income-$6.8M
Net income-$6.8M
Free cash flow-$6.2M
EPS—
Operating cash flow-$6.2M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$6.8M
Net income-$6.8M
Balance sheet
Total assets$42.4M
Total liabilities$23.3M
Total equity$19.1M
Cash & equivalents$19.7M
Long-term debt—
Cash flow
Operating cash flow-$6.2M
CapEx$3.0k
Free cash flow-$6.2M
SBC$312.0k
Highlights
- ▍Operating income -$6.8M
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Operating income -$20.7M.
Revenue—
Operating income-$20.7M
Net income-$20.0M
Free cash flow-$18.5M
EPS—
Operating cash flow-$17.6M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$20.7M
Net income-$20.0M
Balance sheet
Total assets$25.0M
Total liabilities$23.7M
Total equity$1.3M
Cash & equivalents$2.6M
Long-term debt—
Cash flow
Operating cash flow-$17.6M
CapEx$899.0k
Free cash flow-$18.5M
SBC$1.0M
Highlights
- ▍Operating income -$20.7M
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Operating income -$14.0M.
Revenue—
Operating income-$14.0M
Net income-$13.4M
Free cash flow-$11.3M
EPS—
Operating cash flow-$11.2M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$14.0M
Net income-$13.4M
Balance sheet
Total assets$28.9M
Total liabilities$24.0M
Total equity$4.9M
Cash & equivalents$6.8M
Long-term debt—
Cash flow
Operating cash flow-$11.2M
CapEx$76.0k
Free cash flow-$11.3M
SBC$741.0k
Highlights
- ▍Operating income -$14.0M
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Operating income -$27.6M.
Revenue—
Operating income-$27.6M
Net income-$26.6M
Free cash flow-$25.5M
EPS—
Operating cash flow-$24.3M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$27.6M
Net income-$26.6M
Balance sheet
Total assets$39.4M
Total liabilities$23.7M
Total equity$15.7M
Cash & equivalents$16.2M
Long-term debt—
Cash flow
Operating cash flow-$24.3M
CapEx$1.2M
Free cash flow-$25.5M
SBC$1.5M
Highlights
- ▍Operating income -$27.6M
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Operating income -$24.7M.
Revenue—
Operating income-$24.7M
Net income-$23.5M
Free cash flow-$21.3M
EPS—
Operating cash flow-$20.8M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$24.7M
Net income-$23.5M
Balance sheet
Total assets$41.6M
Total liabilities$24.0M
Total equity$17.6M
Cash & equivalents$18.4M
Long-term debt—
Cash flow
Operating cash flow-$20.8M
CapEx$556.0k
Free cash flow-$21.3M
SBC$1.6M
Highlights
- ▍Operating income -$24.7M
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Operating income -$24.7M.
Revenue—
Operating income-$24.7M
Net income-$23.5M
Free cash flow-$21.3M
EPS—
Operating cash flow-$20.8M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$24.7M
Net income-$23.5M
Balance sheet
Total assets$41.6M
Total liabilities$24.0M
Total equity$17.6M
Cash & equivalents$18.4M
Long-term debt—
Cash flow
Operating cash flow-$20.8M
CapEx$556.0k
Free cash flow-$21.3M
SBC$1.6M
Highlights
- ▍Operating income -$24.7M
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Operating income -$27.0M.
Revenue—
Operating income-$27.0M
Net income-$25.7M
Free cash flow-$24.6M
EPS—
Operating cash flow-$23.7M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$27.0M
Net income-$25.7M
Balance sheet
Total assets$45.8M
Total liabilities$25.0M
Total equity$20.8M
Cash & equivalents$20.7M
Long-term debt—
Cash flow
Operating cash flow-$23.7M
CapEx$887.0k
Free cash flow-$24.6M
SBC$1.9M
Highlights
- ▍Operating income -$27.0M
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Operating income -$27.0M.
Revenue—
Operating income-$27.0M
Net income-$25.7M
Free cash flow-$24.6M
EPS—
Operating cash flow-$23.7M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$27.0M
Net income-$25.7M
Balance sheet
Total assets$45.8M
Total liabilities$25.0M
Total equity$20.8M
Cash & equivalents$20.7M
Long-term debt—
Cash flow
Operating cash flow-$23.7M
CapEx$887.0k
Free cash flow-$24.6M
SBC$1.9M
Highlights
- ▍Operating income -$27.0M
Valuation FY
Market price
$1,33
Market cap
$109.7M
Enterprise valueⓘ
$90.0M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
5.8x
P / Tangible bookⓘ
5.8x
Tangible book
$19.1M
Net cashⓘ
$19.7M
Current ratioⓘ
3.2
Debt / equityⓘ
—
ROAⓘ
-16.0%
ROEⓘ
-35.5%
Cash conversionⓘ
91.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
-4.0%
Revenue by segment
Drug Delivery Systems & Packaging—
low · business_description · 2026-07-03
Neuroscience Devices—
low · business_description · 2026-07-03
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 55 %
EPS
Consensus EPS
-0,34
Predicted surprise
-0,08
Beat probability
55 %
Analysts
4
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio -0,05 · as of 2026-07-14 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,34 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -28,6M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 5 %
Probability
5 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-16 · 1,8× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution4 analysts
Strong buy0
Buy4
Hold0
Sell0
Strong sell0
12-month price target$4,62 · Median $4,00
Low $3,50High $7,00
Operating income · consensus-28,6M USD
EPS surprise
−26,5 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$3,50
Mean$4,62
Median$4,00
High$7,00
Spot$1,33
+247.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskLow
Filing-based flags
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
ROE-35,5 %Bottom quartile
D/E0,00Above P75
Cash Conv0,91Below median
Corporate actions / M&A
M&A probabilityconf —
Probability
5 %
Base rate
3 %
Band
Moderate
180-day horizon · target 2027-01-16 · 1,8× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 1 187 133 sh18 grants10 insiders
- Director, Chief Executive Officer · RSUs → Common StockAcquired 100 000grant · 2026-07-28
- Chief Operations Officer · Common Stock Option → Common StockAcquired 160 000 @ $1,31grant · 2026-07-28
- Chief Financial Officer · Common Stock Option → Common StockAcquired 75 000 @ $1,31grant · 2026-07-28
- Chief Financial Officer · RSUs → Common StockAcquired 37 500grant · 2026-07-28
- Director, Chief Executive Officer · Common Stock Option → Common StockAcquired 200 000 @ $1,31grant · 2026-07-28
- Chief Operations Officer · RSUs → Common StockAcquired 80 000grant · 2026-07-28
- Chief Business Officer · RSUs → Common StockAcquired 35 000grant · 2026-07-28
- Chief Business Officer · Common Stock Option → Common StockAcquired 70 000 @ $1,31grant · 2026-07-28
- Chief Medical Officer · Common Stock Option → Common StockAcquired 80 000 @ $1,31grant · 2026-07-28
- Chief Medical Officer · RSUs → Common StockAcquired 40 000grant · 2026-07-28
- Director · Non-Qualified Stock Option (right to buy) → Common StockAcquired 7 965 @ $1,30grant · 2026-07-27
- Director · Non-Qualified Stock Option (right to buy) → Common StockAcquired 36 000 @ $1,22grant · 2026-06-24
- Director · Non-Qualified Stock Option (right to buy) → Common StockAcquired 36 516 @ $1,22grant · 2026-06-24
- Director · Non-Qualified Stock Option (right to buy) → Common StockAcquired 36 516 @ $1,22grant · 2026-06-24
- Director · Non-Qualified Stock Option (right to buy) → Common StockAcquired 36 516 @ $1,22grant · 2026-06-24
- Director, 10% owner · Non-Qualified Stock Option (right to buy) → Common StockAcquired 36 516 @ $1,22grant · 2026-06-24
- Director · Non-Qualified Stock Option (right to buy) → Common StockAcquired 47 212 @ $1,23grant · 2026-01-01
- Director, 10% owner · Non-Qualified Stock Option (right to buy) → Common StockAcquired 72 392 @ $1,23grant · 2026-01-01
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Equitynet_income / total_equity
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Enterprise Valuemarket_cap - net_cash
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
Source documents
- Vivani Medical, Inc. company facts · 2026-07-08
- Vivani Medical, Inc. 10-Q 2026-05-13 · 2026-07-08
- Vivani Medical, Inc. 10-K 2026-03-26 · 2026-07-08
- Vivani Medical, Inc. 10-Q 2025-11-13 · 2026-07-08
- Vivani Medical, Inc. 10-Q 2025-08-13 · 2026-07-08
- 8-K (sec_8k_material) on VANI · 2026-07-08
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Insider activity
Net buying21 buys · 0 sellsnet $29,0M2 insiders · last 365d
- Director, 10% owner · Common StockBought 793 650 @ $1,26$1 000K · 2026-07-15
- Director, 10% owner · Common StockBought 1 587 301 @ $1,26$2,0M · 2026-06-15
- Director, 10% owner · Common StockBought 1 587 301 @ $1,26$2,0M · 2026-05-15
- Director, 10% owner · Common StockBought 1 587 301 @ $1,26$2,0M · 2026-04-15
- Director, 10% owner · Common StockBought 1 310 680 @ $1,03$1,4M · 2026-03-15
- Director, 10% owner · Common StockBought 264 551 @ $1,26$333K · 2026-03-15
- Director, 10% owner · Common StockBought 1 601 941 @ $1,03$1,6M · 2026-02-15
- Director, 10% owner · Common StockBought 264 551 @ $1,26$333K · 2026-02-15
- Director, 10% owner · Common StockBought 1 351 351 @ $1,48$2,0M · 2026-01-27
- Director, 10% owner · Common StockBought 264 551 @ $1,26$333K · 2026-01-15
- Director, 10% owner · Common StockBought 1 473 214 @ $1,12$1,6M · 2026-01-15
- Director · Common StockBought 20 000 @ $1,23$25K · 2025-12-29
- Director, 10% owner · Common StockBought 264 551 @ $1,26$333K · 2025-12-15
- Director, 10% owner · Common StockBought 1 473 214 @ $1,12$1,6M · 2025-12-15
- Director, 10% owner · Common StockBought 264 550 @ $1,26$333K · 2025-11-15
- Director, 10% owner · Common StockBought 1 473 214 @ $1,12$1,6M · 2025-11-15
- Director, 10% owner · Common StockBought 3 703 703 @ $1,62$6,0M · 2025-10-27
- Director, 10% owner · Common StockBought 1 473 214 @ $1,12$1,6M · 2025-10-15
- Director, 10% owner · Common StockBought 264 550 @ $1,26$333K · 2025-10-15
- Director, 10% owner · Common StockBought 1 473 215 @ $1,12$1,7M · 2025-09-15
- Director, 10% owner · Common StockBought 595 238 @ $1,26$750K · 2025-09-15
Short positioning
354.4Kshares short-18.1% vs prior
1days to cover
45.8%short of daily vol
20fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
VANICanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskLow
Source documents mention dilution or offering risk.
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -1.2%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 15.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -5.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Return on equity (FY 2025-12-31): 169.2%Derived (calculated)
- Return on assets (FY 2025-12-31): 67.5%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.71xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.50xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 111.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -11.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -10.7%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 13.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -17.0%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -11.7%Derived (calculated)
- Capex (annual): USD 1.17MSEC XBRL filing
- Shareholders' equity (annual): USD 15.73MSEC XBRL filing
- Current liabilities (annual): USD 6.6MSEC XBRL filing
- Total operating expenses (annual): USD 27.56MSEC XBRL filing
- Net income (annual): USD 26.61MSEC XBRL filing
- Operating income (annual): USD -27.56MSEC XBRL filing
- R&D expense (annual): USD 18.13MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-28INSIDERMendelsohn Adam acquired 200.0k sh Common Stock Option — Director, Chief Executive Officer
2026-07-28INSIDERBaldor Anthony acquired 37.5k sh RSUs — Chief Financial Officer
2026-07-28INSIDERBaldor Anthony acquired 75.0k sh Common Stock Option — Chief Financial Officer
2026-07-28INSIDERLe Truc acquired 160.0k sh Common Stock Option — Chief Operations Officer
2026-07-28INSIDERLe Truc acquired 80.0k sh RSUs — Chief Operations Officer
2026-07-28INSIDERMendelsohn Adam acquired 100.0k sh RSUs — Director, Chief Executive Officer
2026-07-28INSIDERPorter Lisa Ellen acquired 40.0k sh RSUs — Chief Medical Officer
2026-07-28INSIDERPorter Lisa Ellen acquired 80.0k sh Common Stock Option — Chief Medical Officer
2026-07-28INSIDERDwyer Donald acquired 35.0k sh RSUs — Chief Business Officer
2026-07-28INSIDERDwyer Donald acquired 70.0k sh Common Stock Option — Chief Business Officer
2026-07-27INSIDERBRADBURY DANIEL acquired 8.0k sh Non-Qualified Stock Option (right to buy) — Director
2026-07-16 12:49 UTCNEWSHandelsavisen revises Vivani Medical thesis after sector classification audit → Internal data correction triggers fresh analysis of the medical device firm, reinforcing a cautious stance amid weak fundamentals.
2026-07-15INSIDERWilliams Gregg bought 793.6k sh — Director, 10% owner ~$1000k
2026-07-08 04:39 UTCFILINGMaterial 8-K
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-24 00:00 UTCINSIDER6 insider transactions — 2026-06 · net buy $2.0M 5 derivative
2026-06-24 00:00 UTCINSIDER6 insider transactions — 2026-06 · net buy $2.0M 5 derivative
2026-06-24INSIDERMoretti August J acquired 36.0k sh Non-Qualified Stock Option (right to buy) — Director
2026-06-24INSIDERBRADBURY DANIEL acquired 36.5k sh Non-Qualified Stock Option (right to buy) — Director
2026-06-24INSIDERWilliams Gregg acquired 36.5k sh Non-Qualified Stock Option (right to buy) — Director, 10% owner
2026-06-24INSIDERPopoff Alexandra L. acquired 36.5k sh Non-Qualified Stock Option (right to buy) — Director
2026-06-24INSIDERMendelsohn Aaron acquired 36.5k sh Non-Qualified Stock Option (right to buy) — Director
2026-06-21 02:57 UTCHOLDERInstitutional holding changed
2026-06-21 02:57 UTCHOLDER1 institutional position change flagged
2026-06-15INSIDERWilliams Gregg bought 1.59M sh — Director, 10% owner ~$2.00M
2026-05-15 00:00 UTCINSIDER1 insider transaction — 2026-05 · net buy $2.0M
2026-05-15 00:00 UTCINSIDER1 insider transaction — 2026-05 · net buy $2.0M
2026-05-15INSIDERWilliams Gregg bought 1.59M sh — Director, 10% owner ~$2.00M
2026-04-15 00:00 UTCINSIDER1 insider transaction — 2026-04 · net buy $2.0M
2026-04-15 00:00 UTCINSIDER1 insider transaction — 2026-04 · net buy $2.0M
2026-04-15INSIDERWilliams Gregg bought 1.59M sh — Director, 10% owner ~$2.00M
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -6.8M
Showing the 40 most recent of 73 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage